Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
ZBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.50 - $26.25
Previous CloseN/A
Volume96.53K
Average Volume (3M)373.56K
Market Cap
$323.04M
Enterprise ValueN/A
Total Cash (Recent Filing)56.86M
Total Debt (Recent Filing)257.00K
Price to Earnings (P/E)―
Beta0.84
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,791,040
10 Day Avg. Volume166,358
30 Day Avg. Volume373,559
Standard Deviation0.37
R-Squared0.30
Alpha-0.13
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$29.75Price Target Upside293.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCompany has demonstrated distinctive inhibition MOA of obexelimab, thoughtful franchise strategy, solid preclinical/clinical data and 3 late-stage ongoing clinical trials.
Franchise StrategyZenas entered into a license agreement with Bristol-Myers Squibb granting an exclusive license to obexelimab in the Asian BMS territory, supporting the developmental merits of Zenas’ autoimmune platform.
Product PipelineObexelimab represents a franchise within a single asset, targeting multiple indications in the I&I space, with IgG4-RD leading the way.
Bears Say
Clinical Development ChallengesThe decision to not progress obexelimab in wAIHA was driven by the time and resources required to conduct a Phase III program.
Investor ConcernsZBIO shares have faced pressure due to investor concerns on competition for obexelimab in IgG4-RD and the lack of near-term data catalysts.
Stock PerformanceStock performance has been underwhelming since IPO, which is a disconnect from the fundamental value.
---
Options Prices
Currently, No data available
---
Ownership Overview
40.40% Insiders
6.67% Mutual Funds
44.77% Other Institutional Investors
6.06% Public Companies and Individual Investors
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $7.50 and its highest was $26.25 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $323.04M.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Nov 12, 2024. The company reported -$5.02 earnings per share for the quarter, missing the consensus estimate of -$0.951 by -$4.069.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 41,791,040 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$5.02 in its last earnings report, missing expectations of -$0.951. Following the earnings report the stock price went down -3.103%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
---
Zenas BioPharma, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.75 (293.00% Upside)
$29.75 (293.00% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $867.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 14.2%
Last 30 Days ▲ 14.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Our lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We are developing obexelimab for patients in several autoimmune diseases.
---
ZBIO Stock 12 Month Forecast
Average Price Target
$29.75
▲(293.00% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering ZBIO
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-30.70%
assigned a buy rating last month
Copying Roger Song's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -30.70% per trade.
---